Navigation Links
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
Date:1/4/2011

onducting the study at sites within and outside the United States.

Naive Arm

Approximately 100 treatment-naive HCV patients are expected to receive ANA598 in combination with SOC and 33 treatment-naive HCV patients are to receive placebo plus SOC.  Treatment duration for naive patients will be response-guided; patients who achieve undetectable levels of virus at Week 8 and maintain undetectable levels of virus will be scheduled to conclude all treatment at Week 28.  For naive patients with detectable virus at Week 8 dosing with ANA598, or placebo, and SOC is planned to continue through Week 48.  The Company expects to receive Week 8 antiviral response data by the end of the second quarter of 2011, Week 12 antiviral response data in the third quarter of 2011 and Week 24 antiviral response data in the fourth quarter of 2011.

Treatment-Experienced Arm, Including Prior Null Responders

Approximately 80 patients who were partial responders during, or relapsers after, a prior course of therapy with SOC alone are expected to receive ANA598 in combination with SOC, and 33 corresponding patients are to receive placebo plus SOC.  Additionally, approximately 28 prior null responder patients are to receive ANA598 in combination with SOC.  All treatment-experienced patients who receive ANA598 are scheduled to receive triple combination therapy for 48 weeks.  For the treatment-experienced patients, the Company expects to receive Week 12 antiviral response data in the third quarter of 2011 and Week 24 antiviral response data in the fourth quarter of 2011.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable wit
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
2. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
3. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
4. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
6. Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
7. Anadys Retains Lazard as Strategic Advisor
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 Patterson Medical, formerly the ... PDCO ), is now an independent company with ... Patterson Medical by Madison Dearborn Partners (MDP).  ... for a transition period before rebranding as the ... medicine products.  With the focused resources and expertise ...
(Date:8/28/2015)... 28, 2015 Research and ... the "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... Novartis, ranibizumab was approved by CFDA to treat wet ... Lucentis, a product of Novartis, is available in the ... self- developed drug for the treatment of wet AMD ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... NEW YORK, Oct. 27 Intercept Pharmaceuticals, Inc., today ... double-blind Phase II clinical trial of INT-747 in ... evaluated the effects of adding one of three doses ... in patients who did not respond adequately to UDCA ...
... Pharmaceuticals, Inc. today announced $4.5 million in Series A and ... complete the company,s ongoing Phase I/IIa trial of BP-GMAX-CD1 in ... for Phase IIb trials. The company anticipates reporting initial results ... new funding brings the total raised to date to $8.5 ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis 3Bellicum Pharmaceuticals Announces $4.5 Million in New Funding 2
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... to insufficient scrotal support and protection against dribbled urine and sweat. "In order ... Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and President of ... increase acceptance of the chiropractic field in the military. All too often VA hospitals ... Chiropractic was made available to the VA program over a decade ago, the reality ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... Cross and its,affiliates and The Children,s Hospital of ... seven-year agreement. A term of this length is,unusual ... history of this key partnership.,The extended contract will ... Children,s Hospital, serving the,special health care needs of ...
... 4 Perrigo Company,(Nasdaq: PRGO ; TASE) ... mg,Omeprazole delayed released tablets to its retail customers. ... dose as Prilosec OTC(R). Under terms,of an agreement ... exclusive marketer and distributor for the store brand ...
... For patients with acute kidney injury (AKI), an external ... injured kidneys and significantly reduces the risk of death, ... May Journal of the American Society of Nephrology. , ... and effective for desperately ill patients with AKI. ...
... DETROIT, March 4 Metro Parent and Henry Ford ... known TV,and movie personality, and best-selling author of Louder ... metro Detroit area. McCarthy will,be the keynote speaker at ... the Troy Hilton, an event designed to educate locals ...
... similar prevalence of adverse drug reactions in the treatment ... likely than their male counterparts to be treated with ... by researchers at Rush University Medical Center. The study ... Gender Medicine. , Developments in disease recognition and novel ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
Cached Medicine News:Health News:Independence Blue Cross and The Children's Hospital of Philadelphia Reach Seven-Year Agreement 2Health News:Independence Blue Cross and The Children's Hospital of Philadelphia Reach Seven-Year Agreement 3Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 2Health News:Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets 3Health News:'Renal Assist Device' reduces risk of death from acute kidney failure 2Health News:TV Personality and Best-Selling Author Jenny McCarthy Comes to Detroit to Share Her Story of the Struggles and Triumphs of Raising Her Son, Evan, During a Day-Long Autism Workshop 2Health News:Women are treated less frequently than men with statins, aspirin and beta-blockers 2Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2
... is a mini glaucoma ... of filtration surgery for patients ... trabeculectomy, the shunt reduces the ... humor from the anterior chamber ...
... rings, Type 14, 14A and 14C have been ... diameters to accommodate the variations in the size ... capsular tension rings are designed to stabilize the ... a large panel of U.S. ophthalmologists. For ...
Hardee bone rongeur made with the highest quality to meet the exacting standards expected in your surgical specialty....
Traditional design utility pliers have adjustable jaws. Good all purpose plier for handling Steinmann Pins, K-Wires, screws and rods. 10mm jaw tip....
Medicine Products: